1. REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson;Crye;mckesson.com,2021
2. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study;Cutler;Blood,2021
3. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease;Jagasia;J. Clin. Oncol.,2021
4. U.S. FDA Grants Full Approval of REZUROCK™ (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD);Cavaleri;Kadmon Holdings, Inc.,2021
5. FDA approves belumosudil for chronic graft-versus-host disease;FDA.GOV,2021